Nature Cell’s Stem Cell Alzheimer’s Therapy Advances Amid Failures
Nature Cell is set to begin a groundbreaking clinical trial in the US of a novel autologous stem cell therapy for Alzheimer's disease, a new approach likely to gain attention amid other high profile failures in the challenging indication.
You may also be interested in...
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.